223 related articles for article (PubMed ID: 34798487)
21. Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression.
Park M; Newman LE; Gold PW; Luckenbaugh DA; Yuan P; Machado-Vieira R; Zarate CA
J Psychiatr Res; 2017 Jan; 84():113-118. PubMed ID: 27718369
[TBL] [Abstract][Full Text] [Related]
22. Ketamine's effectiveness in unipolar versus bipolar depression.
Fond G; Boyer L
Psychopharmacology (Berl); 2014 Nov; 231(22):4417-8. PubMed ID: 25315362
[No Abstract] [Full Text] [Related]
23. Ketamine and Other NMDA Antagonists: Early Clinical Trials and Possible Mechanisms in Depression.
Newport DJ; Carpenter LL; McDonald WM; Potash JB; Tohen M; Nemeroff CB;
Am J Psychiatry; 2015 Oct; 172(10):950-66. PubMed ID: 26423481
[TBL] [Abstract][Full Text] [Related]
24. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
25. Central nervous system-related safety and tolerability of add-on ketamine to standard of care treatment in treatment-resistant psychotic depression in patients with major depressive disorder and bipolar disorder.
Gałuszko-Wȩgielnik M; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ; Pastuszak M
Front Neurosci; 2023; 17():1214972. PubMed ID: 37496742
[TBL] [Abstract][Full Text] [Related]
26. Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review.
Cooper MD; Rosenblat JD; Cha DS; Lee Y; Kakar R; McIntyre RS
World J Biol Psychiatry; 2017 Sep; 18(6):410-423. PubMed ID: 26752601
[TBL] [Abstract][Full Text] [Related]
27. Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressant.
Kokane SS; Armant RJ; Bolaños-Guzmán CA; Perrotti LI
Behav Brain Res; 2020 Apr; 384():112548. PubMed ID: 32061748
[TBL] [Abstract][Full Text] [Related]
28. Ketamine as Add-On Treatment in Psychotic Treatment-Resistant Depression.
Gałuszko-Węgielnik M; Chmielewska Z; Jakuszkowiak-Wojten K; Wiglusz MS; Cubała WJ
Brain Sci; 2023 Jan; 13(1):. PubMed ID: 36672123
[TBL] [Abstract][Full Text] [Related]
29. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
[TBL] [Abstract][Full Text] [Related]
30. A systematic review of therapeutic ketamine use in children and adolescents with treatment-resistant mood disorders.
Kim S; Rush BS; Rice TR
Eur Child Adolesc Psychiatry; 2021 Oct; 30(10):1485-1501. PubMed ID: 32385697
[TBL] [Abstract][Full Text] [Related]
31. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
32. Psychotic Depression: Diagnosis, Differential Diagnosis, and Treatment.
Dubovsky SL; Ghosh BM; Serotte JC; Cranwell V
Psychother Psychosom; 2021; 90(3):160-177. PubMed ID: 33166960
[TBL] [Abstract][Full Text] [Related]
33. Ketamine's dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders.
Glue P; Medlicott NJ; Harland S; Neehoff S; Anderson-Fahey B; Le Nedelec M; Gray A; McNaughton N
J Psychopharmacol; 2017 Oct; 31(10):1302-1305. PubMed ID: 28441895
[TBL] [Abstract][Full Text] [Related]
34. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
Bobo WV; Vande Voort JL; Croarkin PE; Leung JG; Tye SJ; Frye MA
Depress Anxiety; 2016 Aug; 33(8):698-710. PubMed ID: 27062450
[TBL] [Abstract][Full Text] [Related]
35. [Ketamine's antidepressant effect: focus on ketamine mechanisms of action].
De Maricourt P; Jay T; Goncalvès P; Lôo H; Gaillard R
Encephale; 2014 Feb; 40(1):48-55. PubMed ID: 24434007
[TBL] [Abstract][Full Text] [Related]
36. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
37. mTORC1 inhibitor effects on rapid ketamine-induced reductions in suicidal ideation in patients with treatment-resistant depression.
Averill LA; Averill CL; Gueorguieva R; Fouda S; Sherif M; Ahn KH; Ranganathan M; D'Souza DC; Southwick SM; Sanacora G; Duman RS; Krystal JH; Abdallah CG
J Affect Disord; 2022 Apr; 303():91-97. PubMed ID: 35101523
[TBL] [Abstract][Full Text] [Related]
38. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
[TBL] [Abstract][Full Text] [Related]
39. N,N-dimethylglycine differentially modulates psychotomimetic and antidepressant-like effects of ketamine in mice.
Lin JC; Chan MH; Lee MY; Chen YC; Chen HH
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Nov; 71():7-13. PubMed ID: 27296677
[TBL] [Abstract][Full Text] [Related]
40. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder.
Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Furey ML; Zarate CA
Int J Neuropsychopharmacol; 2014 Oct; 18(1):. PubMed ID: 25539512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
